Does the E138A Mutation in ASPIRE Seroconverters Affect Susceptibility to Dapivirine?

Kerri J Penrose¹, Breanna J Goetz¹, Kelley C Gordon¹, Daniel W Szydlo², Marla J Husnik², Thesla Palanee-Phillips³, Jared M Baeten⁴, John W Mellors¹, Urvi M Parikh¹ ¹University of Pittsburgh, Pittsburgh, PA, USA, ²Statistcal Center for HIV/AIDS Research and Prevention (SCHARP), Seattle, WA, USA, ³Wits Reproductive Health and HIV Institute, Johannesburg, South Africa, ⁴University of Washington, Seattle, WA, USA

microbicide trials network


Background

- ASPIRE was a safety and effectiveness study of the non-nucleoside reverse transcriptase inhibitor (NNRTI) dapivirine (DPV)-containing vaginal ring for HIV-1 prevention conducted at 15 sites in South Africa, Zimbabwe, Malawi and Uganda.
- E138A is a polymorphism that occurs naturally in 5% of treatment-naïve HIV-1 subtype C-infected individuals.
- E138A has been shown in vitro to cause 3-fold resistance to other diarylpyrimidine (DAPY) class inhibitors like etravirine and rilpivirine. Mutations at codon 138 are frequently selected in therapy failures from DAPY class NNRTIs.
- The effect of E138A on DPV susceptibility is unknown.
- E138A was the most common NNRTI associated drug resistance mutation (DRM) found in ASPIRE. Prevalence of E138 mutations were not significantly different by arm (Ref1).
- This study evaluates the prevalence and phenotypic effect of E138A in individuals who seroconverted in the ASPIRE study.

Methods

Sample selection: Population sequencing was performed on plasma from 164 seroconverters from ASPIRE. Samples with mutations in RT codon 138 were selected for phenotypic testing. Matched samples (by study arm, viral load, and site) containing no HIV-1 DRM were also tested as controls.

	Description	Sequence Coverage	Plasma HIV-1 RNA Cut-Off	Mixture Cut-Off	Analysis	3. Plasma derived red
Genotyping Assay	In-house Sanger sequencing based population genotyping using primers optimized for non-B HIV-1 subtypes	Pro (aa 1 – 99) full-length RT (aa 1-560)	≥ 200 copies/ml	>20%	Stanford Genotypic Resistance Interpretation Algorithm v7.0	NNRTIS. 8.0 7.0 * 6.0 6.0
Phenotyping Assay	In-house population phenotyping using plasma- derived recombinant virus and TZM-bl cell line	full-length RT (aa 1-560)	≥ 200 copies/ml	Not established	Linear mixed-effects models were used with Satterthwaite approximations to determine significance, with Bonferroni corrections for multiple comparisons	5.0 4.0 3.0 2.0 1.0
Generate	Phenotyping Assay Wor Extract HIV-1 RNA from patie	ent plasma	560)	pBR322 3' LTR Amp Nef Tat Rev pxxLAI 3D X viral vect		DPV1 DPV2 *Fold change (FC) was cal †FC values exceed the sca †NVP (nevirapine), EFV (et Conclusio
	Clone full-length HIV-1 RT into Is with plasma-derived viral vect susceptibility to DPV, NVP and E	or and prepare vira		Q (AA 1-319) Do	Pol Kho1 Pol	 E138A is a naturally others. Cervical tise fold. The frequency and Although the low f vaginal ring and is reader.



The Microbicide Trials Network is funded by the National Institute of Child Health and Human Development and the National Institute of Mental Health, all components of the U.S. IM1AI068633, UM1AI068633, UM1AI068633, UM1AI068633, UM1AI068615, UM1 National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This study is also made possible through the generous support of the American people through the United States Agency for International Development (USAID) and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The contents are the responsibility of the University of Pittsburgh and do not necessarily reflect the views of USAID, PEPFAR or the United States Government. Cooperative agreement AID-OAA-A-15-00031.

The International Partnership for Microbicides (IPM) developed the dapivirine ring and supplied the rings used in this trial.

Mutation	PLB Ring	DPV Ring
	N = 96	N = 68
V90I	1 (1%)	2 (3%)
L100l	0 (0%)	0 (0%)
K101E	1 (1%)	1 (1.5%)
K103N	1 (1%)	2 (3%)
K103S	0 (0%)	1 (1.5%)
V106M	0 (0%)	1 (1.5%)
V108I	0 (0%)	1 (1.5%)
E138A	5 (5%)	3 (4%)
E138G	0 (0%)	1 (1.5%)
E138K	0 (0%)	0 (0%)
V179D	2 (2%)	1 (1.5%)
V179I/T	0 (0%)	1 (1.5%)
Y181C	0 (0%)	0 (0%)
H221Y	1 (1%)	1 (1.5%)

HIV-1 NNRTI resistance mutations found in the ASPIRE seroconverters

Results

genotypic backgrounds but not others.


DPV Susceptibility						
Arm and Participant	Genotype	IC ₅₀ ±SD§(nM)	Fold-Change [¶]	p-value ^{\\}	Plasma Drug levels (pg/mL)**	
DPV WT [‡]	wild type	0.7 ± 0.1			206	
DPV1	E138A, V179D	0.6 ± 0.1	0.9	1.00	508	
DPV2*	E138A, V179I/T	4.2 ± 1.4	6	<0.001	182	
DPV3*	V108I/V, E138A	1.5 ± 0.3	2.1	<0.001	73.6	
DPV4*	K101E, E138G	4.6±1.2	6.6	<0.001	477	
PLB WT [‡]	wild type	1.2± 0.5				
PLB1*	K101E, E138A	4.3 ± 1.9	3.6	<0.001		
PLB2*	E138A	3.9 ±1.2	3.3	<0.001		
PLB3	E138A	1.2± 0.1	1	1.00		
PLB4	E138A	2.7 ± 0.3	2.3	0.12		
PLB5	E138A	1.1 ± 0.2	0.9	1.00		

*These samples display a significant change in susceptibility compared with wild type samples from the same study arm.

[†]DPV and PLB WT were generated by making a composite IC₅₀ from plasma-derived recombinant viruses HIV-1 that had no NNRTI DRMs (DPV WT n=3, PLB WT n=5). §IC₅₀ values were generated for each plasma-derived recombinant virus in 3 independent experiments. **\P**Fold-Change was calculated as IC₅₀ of mutant/wildtype in each arm. Np-values were calculated using Linear mixed-effects models and used with Satterthwaite approximations to determine significance, with Bonferroni corrections for multiple comparisons . **Plasma DPV levels were measured from the same blood draw collected for phenotypic testing. Plasma DPV levels of ≥95pg/mL indicate some level of adherence. The average DPV level is shown for the wild type samples.

1. Plasma-derived codon 138 mutations confer low level resistance to DPV in some

recombinant viruses display variable cross-resistance to other



ons

ly occurring polymorphism in HIV-1 subtype C that is associated with modest reductions in DPV susceptibility in some RT backgrounds but not ssue and cervical vaginal fluid DPV concentrations from regular ring use exceed the highest DPV IC50s of isolates containing E138A by 40 to 400-

d extent of reduced susceptibility to DPV associated with E138A as the major variant was independent of the ASPIRE study arm. r frequency of E138A limited the sample size, these phenotypic data provide reassurance that the E138A mutation was not selected by the DPV s unlikely to reduce efficacy of the DPV vaginal ring for HIV-1 prevention.


[DPV] usted IC


* These samples display significant change in susceptibility compared with wild type samples from the same study arm. †DPV in-vivo protein binding and estimated IC90 were calculated by multiplying IC50 (ng/mL) by a factor of 7.8 (Ref2). [‡]Mean cervical tissue (600 ng/mL) and cervical vaginal fluid (5,700 ng/mL) DPV concentrations found after 28 days (D28) of DPV ring use in the Phase 1 MTN-013 study (Ref3).

Ref 2) Penrose KJ, et al. 2016. Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals on Failing First-Line Antiretroviral Therapy in South Africa. ntimicrob Agents Chemother doi:10.1128/AAC.01805-16. (Ref 3) Chen BA, et al. 2015. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial. J Acquir Immune Defic Syndr **70:**242-249.

Arm a DPV W DPV1 DPV2

PLB W PLB2 PLB3 PLB4 PLB5





4. Plasma-derived recombinant viruses display generally low but variable cross-resistance to other NNRTIs.

		NVP		EFV		RPV		ETR	
and cipant	Genotype	IC ₅₀ (nM)	Fold- Change						
VT	wild type	36 ± 13		0.7 ± 0.1		0.3 ±0.03		0.9 ± 0.2	
	E138A, V179D	58	1.6	0.7	1.0	0.2	0.7	0.7	0.8
	E138A, V179I/T	376	11	1.7	2.4	0.6	2.0	3.2	3.6
	V108I/V, E138A	79	2.2	0.9	1.3	0.2	0.7	2.3	2.6
	K101E, E138G	23	0.6	0.7	1.0	0.5	1.7	1.1	1.2
VT	wild type	46 ± 23		0.9 ± 0.4		0.4 ± 0.1		1.2 ± 0.2	
	K101E, E138A	864	19	3.3	3.7	1.3	3.3	2.6	2.2
	E138A	119	2.6	1.1	1.2	0.7	1.8	2.0	1.7
	E138A	21	0.5	0.6	0.7	0.3	0.8	1.2	1.0
	E138A	34	0.7	0.5	0.6	0.3	0.8	0.9	0.8
	E138A	217	4.7	1.1	1.2	1.0	2.5	2.3	1.9









